强力霉素对心脏轻链（AL）淀粉样变性早期死亡率的积极影响。 - Suppr

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.

作者信息

Wechalekar A D, Whelan C

机构信息

National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.

出版信息

Blood Cancer J. 2017 Mar 24;7(3):e546. doi: 10.1038/bcj.2017.26.

DOI:10.1038/bcj.2017.26

PMID:28338670

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5380910/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a6f/5380910/b0c31291557a/bcj201726f1.jpg

相似文献

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.

Blood Cancer J. 2017 Mar 24;7(3):e546. doi: 10.1038/bcj.2017.26.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20.

At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.

Ann Hematol. 2017 Dec;96(12):2089-2094. doi: 10.1007/s00277-017-3132-5. Epub 2017 Sep 27.

Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.

Amyloid. 2019;26(sup1):113-114. doi: 10.1080/13506129.2019.1583200.

A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China.

BMC Cardiovasc Disord. 2021 Sep 18;21(1):452. doi: 10.1186/s12872-021-02256-3.

Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis.

Am J Hematol. 2019 Jul;94(7):E194-E196. doi: 10.1002/ajh.25497. Epub 2019 May 3.

Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.

Amyloid. 2019 Jun;26(2):66-73. doi: 10.1080/13506129.2019.1594759. Epub 2019 May 10.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240.

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

Kidney Int. 2017 Dec;92(6):1476-1483. doi: 10.1016/j.kint.2017.05.004. Epub 2017 Jul 18.

Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.

Br J Haematol. 2018 Nov;183(4):557-563. doi: 10.1111/bjh.15541. Epub 2018 Aug 10.

引用本文的文献

Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.

Pharmacotherapy. 2025 Feb;45(2):124-144. doi: 10.1002/phar.4639. Epub 2024 Dec 23.

Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

Curr Oncol. 2024 Sep 18;31(9):5608-5616. doi: 10.3390/curroncol31090415.

Periorbital purpura can be the only initial symptom of primary light chain amyloidosis: A case report.

World J Clin Cases. 2024 Sep 16;12(26):5946-5951. doi: 10.12998/wjcc.v12.i26.5946.

Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.

J Clin Med. 2024 Mar 18;13(6):1744. doi: 10.3390/jcm13061744.

Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.

Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.

Amyloidosis of the Heart and Kidney.

Methodist Debakey Cardiovasc J. 2022 Sep 6;18(4):27-33. doi: 10.14797/mdcvj.1150. eCollection 2022.

Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma.

Case Rep Cardiol. 2022 Jul 30;2022:7846846. doi: 10.1155/2022/7846846. eCollection 2022.

Cardiac Amyloidosis Treatment.

Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):59-72. doi: 10.14797/mdcvj.1050. eCollection 2022.

Clinical trials evaluating potential therapies for light chain (AL) amyloidosis.

Expert Opin Orphan Drugs. 2017;5(8):655-663. doi: 10.1080/21678707.2017.1341834. Epub 2017 Apr 27.

Current Updates on the Management of AL Amyloidosis.

J Hematol. 2021 Aug;10(4):147-161. doi: 10.14740/jh866. Epub 2021 Aug 4.

本文引用的文献

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

Systemic amyloidosis.

Lancet. 2016 Jun 25;387(10038):2641-2654. doi: 10.1016/S0140-6736(15)01274-X. Epub 2015 Dec 21.

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

N Engl J Med. 2015 Sep 17;373(12):1106-14. doi: 10.1056/NEJMoa1504942. Epub 2015 Jul 15.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Leukemia. 2014 Dec;28(12):2311-6. doi: 10.1038/leu.2014.227. Epub 2014 Jul 25.

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.

Leukemia. 2014 Dec;28(12):2304-10. doi: 10.1038/leu.2014.218. Epub 2014 Jul 16.

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.

Blood. 2014 Jun 5;123(23):3543-52. doi: 10.1182/blood-2013-10-525634. Epub 2014 Mar 24.

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-103. doi: 10.1152/ajpheart.00186.2013. Epub 2013 Apr 26.

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.

Blood. 2011 Dec 15;118(25):6610-7. doi: 10.1182/blood-2011-04-351643. Epub 2011 Oct 12.

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4188-93. doi: 10.1073/pnas.0912263107. Epub 2010 Feb 11.

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

J Clin Oncol. 2004 Sep 15;22(18):3751-7. doi: 10.1200/JCO.2004.03.029.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献